IMR Press / JIN / Special Issues / dopaminereceptors

Dopamine Receptors: Latest Advances and Prospects

Submission deadline: 01 November 2022
Special Issue Editor
Pradeep Paudel, PhD
National Center for Natural Products Research, School of Pharmacy, The University of Mississippi, Oxford, MS 38677, USA; Department of Food and Life Science, Pukyong National University, Busan 48513, Republic of Korea
Interests: molecular docking; cannabinoids; natural products; neuronal drug discovery; neurodegenerative diseases
Special Issue Information

Dear Colleagues,

Dopamine (DA) plays a vital role in normal brain processes including memory, motor behavior and reward. Loss of dopaminergic neurons in the substantia nigra contributes to Parkinson's disease, while overactive dopaminergic signaling is an important factor in the positive symptoms of schizophrenia. Hence, dopamine receptors (DRS) are primary targets in the treatment of neurodegenerative diseases such as schizophrenia, Parkinson's disease and Huntington's disease.

DRs are categorized into two classes according to the signals they mediate: D1-like (D1, D5) and D2-like (D2, D3, D4) receptors. DA acts on these receptor families to modulate cellular excitability and synaptic plasticity in a circuit-specific manner, thus ultimately controlling motor behaviors. It has been speculated that cAMP is the primary messenger for DRs in dopamine signaling. However, the complexity in DR crystal structure and signaling provides exciting new avenues for the discovery of antipsychotic drugs. Although current drugs can effectively treat the positive symptoms of schizophrenia, these medications are less effective at treating negative symptoms and cognitive deficits. Hence, there is a critical need to discover and develop novel therapies. The aim of this special issue is to provide an update on the current research status of DRs and on novel trends in this field and future perspectives.

Dr. Pradeep Paudel

Guest Editor

Keywords
dopamine
dopamine receptors
dopamine signaling
neurodegenerative diseases
drug discovery
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1900 USD. Submitted manuscripts should be well formatted in good English.

Back to top